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IMPROVING SYMPTOM CONTROL FOR CHILDREN WITH HEMATOLOGICAL MALIGNANCIES
Improving symptom control and reducing
toxicities for pediatric patients with
hematological malignancies
Lillian Sung,1 Tamara P. Miller,2 and Robert Phillips3
1The Hospital for Sick Children, Toronto, Canada; 2Children’s Healthcare of Atlanta, Emory University, Atlanta, GA; and 3Centre for Reviews and
Dissemination, University of York, York, United Kingdom
The continuing improvement in pediatric cancer survival over time is largely attributable to the availability of intensive
therapies. Increasing attention has been focused on addressing the physical andpsychosocial impacts of cancer and cancer
treatments. Evidence from adult oncology suggests that routine symptom screening and feedback to health care providers
can improve patient-clinician communication, reduce distress, and improve quality of life and may even increase survival.
Manyquestions remain regarding implementation of routine symptom screening in pediatric cancer care, including thebest
symptom assessment instrument and the reporter type and feasibility of integration with electronic health records (EHRs).
Nonsymptom adverse events are also important, for both routine clinical care and adverse event reporting for patients
enrolled in clinical trials. However, traditional mechanisms for reporting adverse events lead to substantial inaccuracies and
are labor intensive. An automated approach for abstraction from EHRs is a potential mechanism for improving accuracy and
reducing workload. Finally, identification of symptom and nonsymptom toxicities must be paired with prophylactic and
therapeutic strategies. These strategies should be based on clinical practice guidelines that synthesize evidence and use
multiprofessional, multidisciplinary expertise to place this evidence in clinical context and create recommendations. How
best to implement clinical practice guidelines remains a challenge, but EHR order sets and alerts may be useful. In summary,
although survival is excellent for pediatric patients receiving cancer therapies, more focus is needed on identification of
symptoms and nonsymptom toxicities and their management. The EHRmay be useful for promoting better supportive care
through these mechanisms.
LEARNING OBJECTIVES
• Understand the importance of routine symptom screening for pediatric patients with hematological malignancies
• Understand the importance of rigorously developed supportive care clinical practice guidelines
Clinical case
A 12-year-old girl who had completed chemotherapy for
acute myeloid leukemia (AML) 6 months ago presented
with bone marrow relapse and was enrolled in a clinical
trial. She stated that she felt “terrible” during most of her
initial treatment and asked whether this next treatment
wouldmake her feel evenworse. Her parentswerewith her
and askedwhether therewas anything that could be done to
help her cope with the toxicities that they were expecting
with the new treatment plan. During the first cycle of che-
motherapy, she developed bacteremia and most likely had
pulmonary aspergillosis. The clinical research associate was
uncertain how to report these toxicities accurately.
Introduction
Pediatric cancer care has benefitted from decades of
successive clinical trials, resulting in continual improve-
ment in survival for children and adolescents with cancer.
Currently, >82% of pediatric patientswith cancer survive at
least 5 years after diagnosis.
1
Although precision medicine
and targeted therapies are promising approaches,
2
the
foundation of pediatric cancer treatment remains con-
ventional chemotherapy, surgery, and radiotherapy. There
has been increasing recognition that these therapies have
an adverse impact on pediatric patients and negatively
affect their quality of life.
3
Consequently, increasing at-
tention has been turned toward addressing the physical
and psychosocial effects of cancer and cancer treatments.



























































































This article focuses on measuring symptoms and nonsymptom
toxicities, in the context of both routine care and clinical trials,
and also addresses the implementation of evidence-based pro-
phylactic and therapeutic strategies to reduce these toxicities.
Symptom screening in routine care
Evidence supporting the hypothesis that routine symptom
screening could improve outcomes first emerged in the adult
cancer literature. Observational studies suggested that rou-
tine collection of patient-reported outcomes would improve
patient-clinician communication,4 reduce distress,5 and improve
quality of life.6 The strongest evidence supporting the impor-
tance of routine symptom screening came from randomized
trials. In one trial, 766 adults with metastatic solid tumors were
randomized into a routine symptom screening group or a
standard-of-care group. The routine symptom screening group
reported 12 common symptoms at clinic visits, and those with
computers also received weekly e-mail prompts. Patients in the
intervention group had significantly improved quality of life,
fewer emergency department visits, and fewer hospitalizations
than those in the standard-of-care control group.6 In a follow-up
analysis, median overall survival was 31.2 months (95% confi-
dence interval, 24.5-39.6) in the routine symptom screening
group vs 26.0 months (95% confidence interval, 22.1-30.9) in
the standard-of-care group (P = .03).7 These studies set the
stage for routine symptom screening in pediatric patients with
cancer.
The choice of instrument to use for routine symptom
screening has been addressed in 3 systematic reviews of system
assessment scales used in pediatric patients with cancer.8-10
Scales most commonly used were the Memorial Symptom As-
sessment Scale (MSAS) 10-18, the MSAS 7-12, the Symptom
Distress Scale, and the Symptom Screening in Pediatrics Tool
(SSPedi). In the most recent systematic review,9 more than half
of the identified studies involved electronic administration of the
symptom assessment scale, which is likely to be well received in
pediatric populations.
SSPedi is a self-reported, 15-item symptom screening tool
created specifically for children receiving cancer treatments
(Figure 1). It measures the extent of discomfort of 15 symptoms
as follows: disappointment or sadness, fear or worry, cranky or
angry disposition, problems with concentration or memory,
bodily or facial changes, fatigue, mouth sores, headache, other
pain, tingling or numbness, vomiting, changes in appetite,
changes in taste, constipation, and diarrhea. SSPedi is available
in paper-based and electronic formats, with the latter having an
audio feature that provides oral reading of the entire instrument
or specific questions. In a multicenter study conducted in
Canada and the United States, SSPedi was reliable (internal
consistency, test-retest reliability, and interrater reliability), valid
(construct validity), and responsive to change in 502 English-
speaking children 8 to 18 years of age who were receiving
cancer therapies.3 It has been translated into Spanish and
French.11 The most commonly reported bothersome symptoms
are shown in Figure 2. A self-report version for children 4 to 7
years of age (mini-SSPedi12) and a proxy-report version for
children 2 to 18 years of age13 have also been developed.
Once an instrument has been identified, an important
question is whether it is the best reporter of the pediatric pa-
tient’s symptoms for clinical implementation. It has long been
recognized that the patient is the best reporter of symptoms.14
However, in pediatric cancer care, there are many scenarios
where pediatric patients either cannot or will not report their
symptoms. Such scenarios include children who are too young,
those with cognitive impairment, or those who are too ill.15 Thus,
an ideal symptom screening approach must be flexible enough
to allow for different types of reporter. We have proposed a
novel method for symptom reporting that involves a structured
dyadic approach. This approach may be particularly useful in
young children.16 Whether the approach is feasible and valid,
however, remains to be answered.
Another important issue is the mechanism by which symp-
toms are collected and reported to health care professionals,
with the 2 broad options being stand-alone systems or inte-
gration into electronic health records (EHRs; Table 1). There are
many advantages of incorporating symptom data into EHRs,
such as efficiency of integration into the workflow of clinicians
and ability to link documented symptoms to orders for inter-
vention. Some vendors (eg, Epic Systems Corporation; Verona,
WI) have developed programs that enable the capture of
patient-reported outcomes. However, these programs gener-
ally have not had modules that are specific to pediatric patients.
Advantages of using stand-alone systems include agility in de-
velopment and modification and compatibility across health
systems with programs from different EHR vendors.
Finally, many practical questions remain to be addressed,
including the ideal frequency for reminders, treatment periods
during which symptoms should be elicited, and the best ap-
proach to providing results of symptom screening to health care
professionals. These questions are likely to be addressed
through the next generation of clinical trials. Nonetheless, the
status of symptom screening in pediatric cancer is currently at
the interface between research and clinical implementation, and
this pendulum is likely to swing toward clinical implementation
in the future.
Capturing nonsymptom toxicities in clinical practice and
clinical trials
Capture of nonsymptom toxicities presents a range of different
challenges. Documentation of toxicities by clinicians is crucial for
understanding a patient’s experience during treatment. Iden-
tification of adverse events (AEs) has been guided for many trials
and patients by the United States National Cancer Institute
Common Terminology Criteria for Adverse Events (CTCAE).17
The CTCAE was developed in 1983 to standardize reporting
of AEs across clinical trials.18-20 However, over time, it has in-
creased in complexity, and the most recent version, CTCAE v5,
includes more than 800 AEs.17,20 Although this complexity in-
creases the potential for more granular reporting, it also raises
concern about potential variation in approaches to identifying
toxicities. Some individuals may report specific signs or symp-
toms, whereas others may report a syndrome that encompasses
many individual toxicities. For example, tumor lysis syndrome
could be reported as the syndrome; as individual components of
hyperkalemia, hyperphosphatemia, hypocalcemia, and hyper-
uricemia; or as both. CTCAE may also be inappropriately used,
depending on the subjective or complex nature of the defini-
tions.21 Variation in reporting approaches and interpretation
causes difficulties in determining accurate toxicity rates for
specific chemotherapy regimens. Further, CTCAE definitions
cause particular challenges for pediatric patients, despite the
addition of pediatric-specific criteria beginning with CTCAE
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v3.0.20 For example, many CTCAE definitions rely on activities of
daily living, which vary widely by age and patient, especially
among children who meet developmental milestones at dif-
ferent ages.20
For patients enrolled in National Cancer Institute cooperative
group trials, reporting of AEs is mandatory. AE rates reported
from clinical trials may be the only source of information re-
garding the toxicity of specific chemotherapy combinations. In
these circumstances, trial AE rates are the only data source that
guides clinicians and patients regarding potential treatment-
related toxicities. On clinical trials, AE capture is typically per-
formed via manual medical record review and reporting by
clinical research associates (CRAs). This process is labor inten-
sive and is only one of many responsibilities that CRAs have.22
Studies have shown that, despite the effort devoted to it,
toxicities are underreported.23,24 One study demonstrated that
AE reports in a trial for pediatric AML had less than 50% sensi-
tivity for 8 of 12 clinically relevant AEs when compared with the
gold-standard chart abstraction.25 This underreporting means
that clinicians do not have an accurate understanding of toxicity
rates and therefore cannot truly prepare patients for potential
toxicity during therapy. Further, phase 3 clinical trials typically
report the highest grade of toxicity experienced during each
chemotherapy course, but the grade may not fully represent the
experience of the patient, especially those receiving prolonged
oral chemotherapy, such as children with acute lymphoblastic
leukemia who are in maintenance therapy. Efforts must be im-
plemented to capture and describe toxicity profiles over time.
Similar to the benefits of using EHRs to collect symptom data
from patients, EHRs may be leveraged to improve capture of
nonsymptom toxicities recorded by clinicians (Table 1). Auto-
mated ascertainment that extracted laboratory data directory
from the EHR, cleaned and processed the data, and graded
laboratory-identified AEs according to CTCAE criteria had high
accuracy at a single institution.26 This automated R package,
ExtractEHR, was implemented at 3 hospitals to obtain laboratory
result data and described accurate rates of laboratory-identified
AEs by chemotherapy course for pediatric patients undergoing
therapy for acute lymphoblastic leukemia or AML.27 Work is
ongoing using the same package to capture non–laboratory-
identified toxicities in pediatric patients with leukemia across
multiple centers. Some institutions have integrated AE capture
systems into the EHR to alert clinicians and track AEs over time,
although no study on this approach has been published from
pediatric centers.28 Trigger tools to alert clinicians to AEs have
also been tested, but a recent study reported low positive
predictive value when using a medication-based trigger.29
Further tailoring of such tools is needed realize clinical benefit.
Table 1. Leveraging EHRs for symptom screening, identification of nonsymptom toxicities, and improving CPG-concordant care
Target areas Components
Facilitate symptom screening Allow patient self-report or proxy report to track symptoms
Allow health care professionals to view symptom scores
Automated capture of toxicities Extraction of data directly from the EHR
Clean data to ensure complete data capture
Remove false results
Grade toxicities according to standard grading systems
Enhance guideline-concordant supportive care Order sets consistent with CPGs
Build alerts when symptoms or other toxicities are identified
Incorporate management recommendations into alerts
Figure 2. Most common severely bothersome symptoms among inpatients 8 to 18 years of age. Adapted from Johnston et al.39



























































































Accurate capture of nonsymptom toxicities is crucial for
understanding the patient’s experience and ultimately im-
plementing measures to reduce toxicity. EHR-based ascertain-
ment has the potential to standardize approaches to capture of
AE and reduce the manual effort required for reporting. If im-
plemented widely, this approach would improve accuracy and
efficiency and free CRAs to capture more complex toxicities or
to perform other responsibilities. This improved knowledge of
AEs would also educate clinicians, improve identification of AEs
for patients in clinical practice, and provide a resource clinicians
can use to guide patients regarding toxicities that may occur
during therapy.
Interventions to improve symptoms
Preventing toxicity and relieving symptoms is essential in the
holistic care of children undergoing cancer therapy and their
families. Delivering this care, triggered by symptom scores or
toxicity assessment or by a predicted high probability that
problems will occur, should be informed by the same high
quality of evidence that underpins cancer care. This belief is the
basis for the development of high-quality supportive care
clinical practice guidelines (CPGs).
CPGs are implementable pieces of evidence synthesis30
(Figure 3). They define the clinical situation to be addressed;
use explicit and comprehensive methods to search for and
appraise the risk of bias of studies that address clinical situations;
and with multiprofessional, multidisciplinary expertise, place
these elements in clinical context to aid in recommending action
(or inaction) and in defining areas of needed research. Guidance
documents, from narrative reviews to expert position statements,
vary in the rigor of their development and in the transparency in
decision making. They require experts to offer their expertise
during development, but their views are considered in the con-
text of the evidence, and the trail of thinking is laid bare, rather
than hidden in wise pronouncements. CPGs are not just meta-
analyses, although high-quality evidence synthesis with system-
atic reviews and similar studies are the bricks fromwhich they are
built.
CPGs should be patient centered, valid, accessible, and
practical. Assessing which outcomes and experiences are of
greatest importance to families and clinicians has been priori-
tized in the development of many supportive care CPGs, in-
cluding the following: avoiding death from toxicity31; shortening
the hospital stay32; and minimizing pain,33 mucositis,34 nausea,35
and fatigue.36 CPG validity can be assessed by using a formal
assessment tool (such as AGREE II [Appraisal of Guidelines for
Research and Evaluation])37 or by using guidelines endorsed by
an organization that has undertaken such an assessment.
Implementation of guidelines, that is, converting their bald
academic recommendations into something the clinical team
can act on, is a separate skill. Local knowledge and significant
leadership are needed to change the behaviors of a clinical
team. A series of studies have been undertaken to assess how
well CPGs effect change and the best techniques for the as-
sessment, but much more research is needed.38 Tools such as
integrated care pathways, prepopulated test order sets, and 1-
touch prescription protocols linked to other elements of the EHR
can help (Table 1). Patient-led interaction and high-quality ed-
ucation linked to emotional motivation may be effective as well.
Printing a flowsheet, e-mailing a 20-page document to the
Figure 3. Definition of a CPG. Adapted from Graham et al.40



























































































clinical team, or silently placing it in an online library wastes the
clinician’s time and breaks the hearts of the EHR developers, as
well as reducing the chances of it being clinically implemented
an improving symptoms.
Back to the clinical case
The patient’s hospital had adopted a systematic approach to
routine symptom screening in the ambulatory and inpatient
settings. Fatigue, nausea, and changes in taste were quickly
deemed extremely bothersome. Based on the hospital’s clinical
pathways, routine physical exercise with a physiotherapist was
implemented. Adherence to a CPG for prevention of nausea and
treatment guidance was closely monitored. Several approaches
to managing the changes in taste were provided, although this
symptom was less well controlled. The hospital also im-
plemented an automated AE capture system, and reports were
validated by the patient’s attending physician. She completed
relapse therapy and reported her experiencewasmuch better in
comparison with the initial therapy, even though the second
treatment had been more intensive.
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